CBR-5884 is a potent, reversible, and selective inhibitor of the autophagy protease ATG4B (IC₅₀ = 1.7 μM). It is primarily utilized in the field of medical research, particularly in the study of cancer therapies and autophagy regulation. By targeting ATG4B, CBR-5884 disrupts lipidation of LC3 and autophagy processes that promote cell proliferation, survival, and tumor growth, making it a valuable tool for understanding and potentially treating various types of cancers. Researchers employ CBR-5884 to investigate its effects on tumor growth inhibition via autophagy blockade and to explore its potential as a therapeutic agent in preclinical studies. Its role in modulating cellular pathways also aids in the development of novel drug candidates for oncology applications.